Heparin-induced thrombocytopaenia (HIT)-an overview: what does the nephrologist need to know and do?

Inpatient citrate-based hemodialysis in pediatric patients. Pediatr Nephrol (2016) 0.75

Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol (2003) 4.86

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.07

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood (2005) 2.08

Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost (2008) 1.75

The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest (2007) 1.71

A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost (2001) 1.50

When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation (2005) 1.45

Heparin-induced thrombocytopenia: diagnosis and management. Circulation (2004) 1.30

Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet (1973) 1.18

Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int (2012) 1.17

Heparin-induced thrombocytopenia. J Thromb Haemost (2003) 1.16

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood (2000) 1.09

Heparin-induced thrombocytopenia: an update. Thromb J (2005) 1.08

Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant (2005) 1.01

Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother (2005) 0.97

Heparin-induced skin lesions. Br J Haematol (1996) 0.93

National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant (2007) 0.91

The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol (1996) 0.90

An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost (2004) 0.89

How I treat heparin-induced thrombocytopenia and thrombosis. Blood (2002) 0.89

Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica (2003) 0.88

Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol (2009) 0.88

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest (1999) 0.85

Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost (1997) 0.85

Who is (still) getting HIT? Chest (2007) 0.85

The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost (2009) 0.84

Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J (2009) 0.83

Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res (2011) 0.79

Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int (1994) 0.78

Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney Int Suppl (1999) 0.78